China NMPA Inspection - Guangdong Kangyingbao Biotechnology Co., Ltd. - September 02, 2019

The National Medical Products Administration (NMPA) of China officially announced an unannounced inspection concerning Guangdong Kangyingbao Biotechnology Co., Ltd. The notification, publicly released on September 2, 2019, under the reference number JGXX-2020-2112, signals a regulatory initiative by the NMPA to assess the company's compliance with established pharmaceutical or cosmetic product standards. This type of inspection is typically conducted without prior warning to ensure that manufacturers consistently maintain quality control and adhere to good manufacturing practices. The primary purpose of such an unannounced visit by a regulatory body like the NMPA is to objectively evaluate a company's operational integrity and its adherence to relevant regulations in real-time. While the document confirms the initiation of this oversight activity involving Guangdong Kangyingbao Biotechnology Co., Ltd., it solely serves as a formal notification. The provided information does not include details regarding the specific dates on which the inspection occurred, any main violations or non-compliance issues discovered during the assessment, or any subsequent required corrective actions imposed by the NMPA. Therefore, the document establishes the regulatory action but does not report on its outcomes or implications for the company.